European Network for Hepatitis B and C Surveillance
The European Network for Hepatitis B and C Surveillance comprises the contact points for Hepatitis B and C surveillance that are nominated by the competent bodies for surveillance in EU/EFTA, and includes both epidemiology and virology experts. It aims to improve collaboration, build capacity and facilitate dissemination of information on hepatitis B and C to inform public health policy and planning across Europe.
From 2011 onwards the enhanced surveillance data on hepatitis B and C has been collected annually and is submitted to the European Surveillance System (TESSy) by the national surveillance contact points in the Member States.
• Improve epidemiological data around hepatitis B and C across Europe
• Collection of annual enhanced surveillance data from European countries
• Production of routine surveillance reports
• Publications based around relevant themes
• Development of alternative sources of epidemiological data for hepatitis B and C
- The incidence and routes of transmission of newly diagnosed cases of hepatitis B and C in the general and vulnerable populations;
- the prevalence of chronic hepatitis B and C virus infection to determine burden of infection (and estimate the proportion undiagnosed) in the general and vulnerable populations;
- the proportion of chronic hepatitis B and C cases that are engaged in care (continuum of care);
- the proportion of newly diagnosed chronic hepatitis B and C presenting late.
- The genotype and sequence distributions of newly acquired hepatitis B and hepatitis C viruses to better follow transmission patterns, the emergence of resistance and vaccine escape mutants and potentially more virulent virus strains (priority on hepatitis C infections);
- and describe the proportion of co-infections (HIV/HBV/HCV/HDV)nd describe the proportion of co-infections (HIV/HBV/HCV/HDV);
- the proportion of HCV re-infections (especially among key risk groups with high incidence e.g. PWIDs)
- To provide data to inform, strengthen and improve the development, evaluation and monitoring of national and EU level hepatitis B and C primary prevention and control programmes (e.g. vaccination, harm reduction);
- To monitor the burden of chronic hepatitis B and C infection and their continuum of care to inform, strengthen and improve the development, evaluation and monitoring of secondary prevention programmes (e.g. screening and high quality care pathways);
- To identify emerging population groups at risk (and changes over time) and in need for targeted prevention measures;
- To report on patient safety from healthcare associated infection and healthcare worker safety from occupational transmission;
- To better describe the prevalence of hepatitis in vulnerable populations – for Hepatitis B: especially MSM, IDU, CSW, migrants and for Hepatitis C: especially IDU, prisoners, blood and blood product recipients, migrants;
- To detect and monitor any multi-state outbreaks of viral hepatitis with respect to source, time, person, population and place in order to provide a rationale for public health action.
More on the topic
HIV/AIDS, sexual transmitted infections and viral hepatitis Programme
This programme was set up in September 2006. The programme covers chlamydia infection, gonorrhoea, syphilis, hepatitis B, hepatitis C, HIV infection and AIDS.Read more
Hepatitis C is a liver disease caused by infection with the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness that lasts only a few weeks to a serious, lifelong illness resulting in cirrhosis and liver cancer.Read more
Hepatitis B is a liver disease that results from infection with the hepatitis B virus (HBV) and is spread through contact with infected body fluids or blood products.Read more
World Hepatitis Day 2018
28 Jul 2018 to 28 Jul 2018 - On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
23 Jul 2018 - People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
11 Dec 2018 - The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.